Pfizer: EU approves Besponsa for leukemia.
(CercleFinance.com) - US drugmaker Pfizer has said that the European Commission has approved Besponsa, a monoclonal antibody targeting cancer cells, to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
This indication includes the treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
With this approval, Besponsa becomes the first and only antibody drug conjugate available for patients with this type of leukemia in the European Union.
Acute lymphoblastic leukemia is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This indication includes the treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
With this approval, Besponsa becomes the first and only antibody drug conjugate available for patients with this type of leukemia in the European Union.
Acute lymphoblastic leukemia is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.
Copyright (c) 2017 CercleFinance.com. All rights reserved.